Document Detail

Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
MedLine Citation:
PMID:  16243800     Owner:  NLM     Status:  MEDLINE    
Serum beta2-microglobulin, the light chain of the HLA class I molecular complex, remains one of the best survival prognostic factors in multiple myeloma, but other HLA class I molecules might be of interest in monoclonal gammopathies. In this study, we evaluate total soluble HLA class I (HLA-Is) and soluble HLA-G (HLA-Gs) in 103 patients with newly diagnosed multiple myeloma, 30 patients with monoclonal gammopathy of undetermined significance (MGUS), and 30 healthy subjects, studying their prognostic value in multiple myeloma. In multiple myeloma patients, HLA-Is and HLA-Gs median values were 0.8 microg/mL and 28 ng/mL, respectively. Median HLA-Is concentration was higher in stage II and III multiple myeloma patients than in stage I multiple myeloma, MGUS, and control patients. Median HLA-Gs was significantly lower in healthy controls than in MGUS and multiple myeloma patients. A high level of HLA-Is (> or =2.1 microg/mL) was predictive of short survival (P = 0.017). For each given level of beta2-microglobulin, the relative risk of death was higher for patients with HLA-Is > or = 2.1 microg/mL than in patients with a lower level (P = 0.047). HLA-Gs, a marker of monoclonal gammopathy, was of no prognostic value, but the addition of HLA-Is to beta2-microglobulin produced an efficient prognostic score (P < 0.0001). HLA-Is is a new marker of multiple myeloma tumor load and provides additional survival prognostic information to beta2-microglobulin.
Xavier Leleu; Gaëlle Le Friec; Thierry Facon; Laurence Amiot; Renée Fauchet; Bernadette Hennache; Valérie Coiteux; Ibrahim Yakoub-Agha; Sylvain Dubucquoi; Hervé Avet-Loiseau; Claire Mathiot; Régis Bataille; Jean-Yves Mary;
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  11     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-24     Completed Date:  2006-02-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  7297-303     Citation Subset:  IM    
Service d'Hématologie, Lille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
HLA Antigens / blood*
Histocompatibility Antigens Class I / blood*
Middle Aged
Multiple Myeloma / blood,  pathology*
Paraproteinemias / blood,  pathology*
Survival Analysis
beta 2-Microglobulin / blood*
Reg. No./Substance:
0/HLA Antigens; 0/HLA-G antigen; 0/Histocompatibility Antigens Class I; 0/beta 2-Microglobulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 1...
Next Document:  Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the...